Search results for "Uncontrolled Study"

showing 3 items of 3 documents

Differential Change of Borderline Personality Disorder Traits During Dialectical Behavior Therapy for Adolescents

2019

Despite the expansion of treatment options for adults with borderline personality disorder (BPD), research on treatment options for adolescent BPD is scarce. The aim of this study was to investigate the impact of dialectical behavior therapy for adolescents (DBT-A) on the individual trait level as primary outcome; and the frequency of suicide attempts and nonsuicidal self-injury, self-reported BPD core pathology, and general psychopathology as secondary outcomes. Seventy-two adolescents (aged 12–17 years) with full- or subsyndromal BPD were treated with DBT-A (25 single sessions, 20 sessions of skills training), and 13 patients (18.1%) withdrew during treatment. From baseline to post-treat…

MaleAdolescentmedicine.medical_treatmentUncontrolled StudyDialectical Behavior Therapybehavioral disciplines and activities03 medical and health sciencesSkills training0302 clinical medicinePrimary outcomeBorderline Personality Disordermental disordersmedicineHumans0501 psychology and cognitive sciencesChildBorderline personality disorder05 social sciencesTreatment optionsmedicine.diseaseDialectical behavior therapy030227 psychiatryPsychiatry and Mental healthClinical PsychologyGeneral psychopathologyTreatment OutcomeTraitFemalePsychology050104 developmental & child psychologyClinical psychologyJournal of Personality Disorders
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

2020

Phosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Prof…

Malemedicine.medical_specialtyPercentileSildenafilUrologymedicine.medical_treatment030232 urology & nephrologyUrologyUncontrolled Studyprostatic neoplasmsSildenafil Citrate03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyErectile DysfunctiontherapeuticsHumansMedicineAdverse effectProstatectomy030219 obstetrics & reproductive medicineFramingham Risk Scorebusiness.industryProstatectomyPenile ErectionOrodispersible filmGeneral MedicinePhosphodiesterase 5 Inhibitorsmedicine.diseaseTreatment OutcomeErectile dysfunctionchemistrybusinessAndrologia
researchProduct